BTIG Reiterates Buy on Avalo Therapeutics, Maintains $40 Price Target
Avalo Therapeutics Inc
Avalo Therapeutics Inc AVTX | 0.00 |
BTIG analyst Julian Harrison reiterates Avalo Therapeutics (NASDAQ:
AVTX) with a Buy and maintains $40 price target.
